The most common side effects of Wegovy are gastrointestinal: nausea, diarrhea, vomiting, and constipation. In clinical trials, nausea affected anywhere from 14% to 61% of people taking the drug, compared to 5% to 22% of those on placebo. These stomach-related issues are the reason most people who quit Wegovy do so, but for the majority of users they’re temporary and manageable, particularly during the early weeks of treatment.
Digestive Side Effects
Nausea is the single most reported side effect. Across the major clinical trials (known as the STEP studies), it showed up in roughly half of participants at higher doses. Diarrhea affected 14% to 36% of users, and constipation hit up to 39%. These numbers are significantly higher than what people on a placebo experienced, confirming that the drug itself, not just the experience of being in a trial, drives these symptoms.
The reason comes down to how semaglutide works. Wegovy mimics a gut hormone called GLP-1, which among other things slows how fast your stomach empties food into the small intestine. That delayed emptying helps you feel full longer (which is part of how the drug causes weight loss), but it also creates the sensation of nausea, bloating, and fullness that many users describe, especially after eating a normal-sized meal. The drug also activates receptors in the brain that can trigger nausea independently of what’s happening in the stomach.
When Side Effects Start and How Long They Last
Wegovy uses a gradual dose escalation: you start at 0.25 mg per week and increase every four weeks over about 16 to 20 weeks until reaching the maintenance dose of 2.4 mg. This slow ramp-up exists specifically to give your body time to adjust. Most gastrointestinal side effects peak when you move to a new dose level and then fade over the following days or weeks.
A multidisciplinary expert panel that reviewed the clinical evidence described these side effects as “transient and of mild to moderate severity in the majority of cases.” Your prescriber may keep you at one dose longer than four weeks if side effects aren’t settling down before moving to the next step. For many people, by the time they reach the maintenance dose, the worst of the nausea has passed.
Practical Ways to Reduce Nausea
Small changes to how and what you eat make a noticeable difference. A clinical consensus panel offered these specific strategies:
- Eat smaller, more frequent meals. Large portions overwhelm a stomach that’s emptying more slowly than usual.
- Choose bland, low-fat foods. Greasy, spicy, or heavily sauced meals are harder to digest and more likely to trigger nausea.
- Stop eating at the first sign of fullness. Your satiety signals will kick in earlier than you’re used to. Pushing past them is a reliable way to feel sick.
- Stay hydrated with small sips. Clear, cool drinks help, but gulping large amounts of liquid can make fullness worse. Soups, liquid yogurt, and gelatin-based foods count toward fluid intake.
- Don’t lie down after eating. Staying upright and taking a light walk can ease digestion.
- Try ginger or mint. Crackers, apples, ginger root, and ginger-based drinks can help settle nausea, as long as at least 30 minutes have passed since your last dose.
- Avoid eating close to bedtime. A slow-emptying stomach plus lying flat is a recipe for overnight nausea.
If vomiting becomes a problem, the priority shifts to hydration. Separating drinks from meals (having fluids 30 to 60 minutes before or after eating, rather than during) can help when nausea or vomiting is persistent.
Gallbladder Problems
Rapid weight loss from any cause raises the risk of gallstones, and Wegovy is no exception. Gallstones form when the liver releases extra cholesterol into bile during fast fat loss, and bile composition shifts in a way that promotes crystallization. Symptoms to watch for include sudden, intense pain in the upper right abdomen, especially after eating fatty food, sometimes with nausea or fever. Gallbladder inflammation (cholecystitis) has been reported in clinical trials and may require surgical removal of the gallbladder.
Pancreatitis
Acute pancreatitis, an inflammation of the pancreas, has been reported both in clinical trials and in post-marketing surveillance. Post-marketing data also includes rare cases of necrotizing pancreatitis, a severe form that has sometimes been fatal. The overall incidence is low, but the symptoms are worth knowing: persistent, severe abdominal pain that radiates to the back, often accompanied by vomiting. This is a medical emergency regardless of whether you’re on Wegovy.
Kidney Injury From Dehydration
Wegovy doesn’t damage the kidneys directly, but the vomiting and diarrhea it causes can lead to dehydration severe enough to trigger acute kidney injury. Reported cases have typically followed a pattern: a patient develops persistent gastrointestinal symptoms, loses too much fluid, and kidney function drops as a result. The risk is higher for people who already have reduced kidney function or who take other medications that stress the kidneys, like certain blood pressure drugs. Staying on top of hydration is especially important if you’re experiencing ongoing vomiting or diarrhea.
Thyroid Tumor Warning
Wegovy carries the FDA’s most serious label warning, a boxed warning, related to thyroid tumors. In animal studies, semaglutide caused dose-dependent thyroid C-cell tumors in rodents at doses comparable to human use. Whether this translates to humans is unknown, and no confirmed link has been established in people. As a precaution, Wegovy is contraindicated if you have a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). A lump in the neck, trouble swallowing, hoarseness, or shortness of breath are symptoms worth reporting promptly.
Mental Health and Suicidal Thoughts
Early reports raised concern about a possible link between GLP-1 drugs and suicidal thoughts, prompting the FDA to investigate. That investigation is now complete, and the agency found no increased risk. A meta-analysis covering 91 placebo-controlled trials and nearly 108,000 patients showed no elevated rates of suicidal ideation, self-harm, depression, anxiety, or psychosis among GLP-1 drug users. A separate real-world study using health insurance claims data from over 2.2 million patients confirmed the finding. Based on this evidence, the FDA has asked manufacturers to remove the suicidal behavior warning from GLP-1 drug labels.
Injection Site Reactions
About 1.4% of Wegovy users in clinical trials reported reactions at the injection site, including redness, itching, inflammation, and irritation. This was only slightly above the 1% rate seen in the placebo group. Rotating your injection site with each weekly dose (alternating between the abdomen, thigh, and upper arm) is the standard way to minimize irritation.
Severe Gastrointestinal Events
Beyond everyday nausea and diarrhea, post-marketing reports have flagged more serious digestive complications: intestinal obstruction (ileus), severe constipation progressing to fecal impaction, and gastroparesis (a condition where the stomach loses the ability to move food through efficiently). These are rare but significant enough that the FDA label now states Wegovy is not recommended for people with severe pre-existing gastroparesis. Persistent or worsening constipation, inability to pass gas, or severe abdominal distension are signs that something beyond typical side effects may be happening.